Microbiome skincare company SkinBioTherapeutics PLC (LON:SBTX) said it has successfully managed to scale up production with no detrimental impact on the effectiveness of its technology.
The material produced, which to date has been manufactured and supplied in a liquid form, has now been successfully freeze-dried.
SkinBio said the ability to freeze dry the material is an important step towards commercialisation as it enables mass production, storage and transportation.
READ SkinBioTherapeutics receives ethics approval for human trial of SkinBiotix
The company was recently given provisional ethics approval from regulators to commence the human study of its technology and this is scheduled to commence next month, subject to the company being confident of the stability of the current formulation over an extended time-frame.
The company said it would publish its full-year results in October but revealed it ended June with a cash balance of £3.2mln, down from £3.6mln at the end of 2017.
"The progress we've made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study,” said Dr Cath O’Neill, the chief executive officer of SkinBio.